NASDAQ:BPMC - Blueprint Medicines Stock Price, Price Target & More

$83.24 -3.53 (-4.07 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$83.24
Today's Range$82.53 - $86.73
52-Week Range$34.38 - $109.00
Volume318,803 shs
Average Volume359,721 shs
Market Capitalization$3.85 billion
P/E Ratio-21.23
Dividend YieldN/A
Beta0.97

About Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines logoBlueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580

Debt

Debt-to-Equity Ratio0.02%
Current Ratio15.98%
Quick Ratio15.98%

Price-To-Earnings

Trailing P/E Ratio-21.23
Forward P/E Ratio-17.16
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.43 million
Price / Sales169.74
Cash FlowN/A
Price / CashN/A
Book Value$14.55 per share
Price / Book5.72

Profitability

EPS (Most Recent Fiscal Year)($3.92)
Net Income$-148,110,000.00
Net Margins-691.30%
Return on Equity-38.79%
Return on Assets-32.32%

Miscellaneous

Employees149
Outstanding Shares43,700,000

How to Become a New Pot Stock Millionaire

Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines (NASDAQ:BPMC) announced its earnings results on Wednesday, February, 21st. The biotechnology company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.07) by $0.16. The biotechnology company had revenue of $1.63 million for the quarter, compared to analyst estimates of $5.28 million. Blueprint Medicines had a negative return on equity of 38.79% and a negative net margin of 691.30%. Blueprint Medicines's quarterly revenue was down 78.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.75) EPS. View Blueprint Medicines' Earnings History.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Blueprint Medicines.

What price target have analysts set for BPMC?

10 analysts have issued twelve-month target prices for Blueprint Medicines' stock. Their forecasts range from $56.00 to $109.00. On average, they expect Blueprint Medicines' stock price to reach $87.7778 in the next year. View Analyst Ratings for Blueprint Medicines.

What are Wall Street analysts saying about Blueprint Medicines stock?

Here are some recent quotes from research analysts about Blueprint Medicines stock:
  • 1. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (2/23/2018)
  • 2. Cowen Inc analysts commented, "We maintain our BUY rating following the Q3/17 results. Histogenics reported zero revenue and a diluted net loss of $5.1M, compared to CG/ consensus of $6.5M/$6.3M net loss, and LPS of $(0.23), compared with CG/consensus estimate of $(0.29)/$(0.28). As anticipated, the Q3 call was largely uneventful as Histogenics awaits one-year data from the NeoCart Phase 3 clinical trial. Management noted that 65% of patients are now at the one-year mark and reiterated their expectation for one-year data to be announced in Q3/18." (11/10/2017)

Who are some of Blueprint Medicines' key competitors?

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the folowing people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 60)
  • Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 47)
  • Mr. Alexis Borisy, Co-Founder & Director (Age 46)
  • Dr. Marion Dorsch Ph.D., Chief Scientific Officer (Age 53)
  • Ms. Tracey L. Mccain Esq., Chief Legal Officer and Exec. VP (Age 50)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Has Blueprint Medicines been receiving favorable news coverage?

Media coverage about BPMC stock has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Blueprint Medicines earned a media sentiment score of 0.04 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $83.24.

How big of a company is Blueprint Medicines?

Blueprint Medicines has a market capitalization of $3.85 billion and generates $21.43 million in revenue each year. The biotechnology company earns $-148,110,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Blueprint Medicines employs 149 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]


MarketBeat Community Rating for Blueprint Medicines (BPMC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  385
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Blueprint Medicines (NASDAQ:BPMC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Blueprint Medicines in the last 12 months. Their average twelve-month price target is $87.7778, suggesting that the stock has a possible upside of 5.45%. The high price target for BPMC is $109.00 and the low price target for BPMC is $56.00. There are currently 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $87.7778$83.7778$83.7778$63.4656
Price Target Upside: 5.45% upside4.24% downside16.58% upside7.28% downside

Blueprint Medicines (NASDAQ:BPMC) Consensus Price Target History

Price Target History for Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines (NASDAQ:BPMC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018WedbushBoost Price TargetOutperform -> Outperform$98.00 -> $106.00HighView Rating Details
4/16/2018JMP SecuritiesSet Price TargetBuy$97.00 -> $109.00HighView Rating Details
2/21/2018CowenReiterated RatingBuyLowView Rating Details
12/11/2017Goldman SachsBoost Price TargetBuy -> Buy$82.00 -> $99.00HighView Rating Details
12/10/2017Raymond JamesSet Price TargetBuy$82.00HighView Rating Details
11/1/2017Canaccord GenuityReiterated RatingBuy$66.00 -> $80.00N/AView Rating Details
10/23/2017Morgan StanleyBoost Price TargetOverweight$45.00 -> $78.00N/AView Rating Details
9/29/2017DA DavidsonInitiated CoverageBuy$90.00HighView Rating Details
9/29/2017BTIG ResearchInitiated CoverageBuy -> Buy$90.00HighView Rating Details
9/5/2017Jefferies GroupReiterated RatingBuy$56.00MediumView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Blueprint Medicines (NASDAQ:BPMC) Earnings History and Estimates Chart

Earnings by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines (NASDAQ:BPMC) Earnings Estimates

2018 EPS Consensus Estimate: ($4.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.13)($0.83)($0.98)
Q2 20182($1.22)($0.88)($1.05)
Q3 20182($1.30)($1.03)($1.17)
Q4 20182($1.33)($1.23)($1.28)

Blueprint Medicines (NASDAQ BPMC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($1.15)N/AView Earnings Details
2/21/2018Q4 2017($1.07)($1.23)$5.28 million$1.63 millionViewN/AView Earnings Details
10/31/2017Q3 2017($0.90)($0.96)$5.35 million$8.07 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.75)($0.86)$5.96 million$5.89 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.73)($0.84)$6.02 million$5.84 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.76)($0.75)$6.31 million$7.69 millionViewListenView Earnings Details
11/10/2016Q316($0.77)($0.62)$6.06 million$6.16 millionViewListenView Earnings Details
8/9/2016Q216($0.73)($0.70)$4.41 million$7.07 millionViewListenView Earnings Details
5/10/2016Q116($0.70)($0.57)$3.24 million$6.90 millionViewListenView Earnings Details
3/11/2016Q415($0.53)($0.58)$2.85 million$4.64 millionViewN/AView Earnings Details
11/9/2015Q3($0.54)($0.47)$1.83 million$3.43 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.44)($0.81)$0.94 million$2.69 millionViewN/AView Earnings Details
6/11/2015Q1 2015($6.20)($8.23)$0.94 million$0.65 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Blueprint Medicines (NASDAQ:BPMC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Blueprint Medicines (NASDAQ BPMC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 97.75%
Insider Trading History for Blueprint Medicines (NASDAQ:BPMC)
Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines (NASDAQ BPMC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2018George DemetriDirectorSell5,492$100.09$549,694.2810,231View SEC Filing  
3/15/2018Marion DorschInsiderSell2,300$100.07$230,161.002,300View SEC Filing  
3/2/2018Jeffrey W AlbersCEOSell20,000$92.57$1,851,400.0020,000View SEC Filing  
2/28/2018Nicholas LydonDirectorSell25,000$87.89$2,197,250.00193,131View SEC Filing  
2/14/2018Daniel LynchDirectorSell12,500$80.42$1,005,250.00174,342View SEC Filing  
2/12/2018Daniel LynchDirectorSell17,500$74.84$1,309,700.00202,812View SEC Filing  
2/12/2018Kate HavilandInsiderSell6,775$74.93$507,650.7512,649View SEC Filing  
11/21/2017Marion DorschInsiderSell18,334$65.45$1,199,960.3018,334View SEC Filing  
11/15/2017Daniel LynchDirectorSell5,000$63.38$316,900.00View SEC Filing  
11/6/2017Anthony L BoralInsiderSell5,000$70.40$352,000.00View SEC Filing  
11/6/2017Jeffrey W AlbersCEOSell30,000$70.31$2,109,300.00View SEC Filing  
10/5/2017Kate HavilandInsiderSell5,449$66.44$362,031.56View SEC Filing  
9/18/2017Daniel LynchDirectorSell2,500$60.00$150,000.00209,342View SEC Filing  
9/18/2017Kate HavilandInsiderSell6,356$60.03$381,550.686,356View SEC Filing  
8/9/2017Anthony L BoralInsiderSell5,000$48.60$243,000.005,000View SEC Filing  
8/8/2017Jeffrey W AlbersCEOSell30,000$49.62$1,488,600.0018,272View SEC Filing  
8/7/2017Jeffrey W AlbersCEOSell20,000$49.08$981,600.0018,272View SEC Filing  
7/5/2017Daniel LynchDirectorSell7,500$55.06$412,950.00211,842View SEC Filing  
7/5/2017Kate HavilandInsiderSell7,265$54.66$397,104.907,265View SEC Filing  
6/28/2017Daniel LynchDirectorSell32,500$50.28$1,634,100.00View SEC Filing  
6/28/2017Jeffrey W AlbersCEOSell20,000$50.47$1,009,400.0047,920View SEC Filing  
6/28/2017Kate HavilandInsiderSell6,357$50.00$317,850.006,357View SEC Filing  
3/16/2017Mark J LevinMajor ShareholderSell30,000$40.88$1,226,400.00116,444View SEC Filing  
2/7/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell1,000,000$35.28$35,280,000.00View SEC Filing  
12/19/2016Kevin P. StarrMajor ShareholderSell106,489$28.19$3,001,924.91View SEC Filing  
12/1/2016Daniel LynchDirectorSell200$30.02$6,004.00255,694View SEC Filing  
10/13/2016Daniel LynchDirectorSell21,800$30.02$654,436.00View SEC Filing  
8/8/2016Jeffrey W AlbersCEOSell17,000$22.86$388,620.0076,494View SEC Filing  
6/3/2016Jeffrey W AlbersCEOSell17,000$20.03$340,510.0092,486View SEC Filing  
4/13/2016Christoph LengauerInsiderSell15,872$20.01$317,598.7256,657View SEC Filing  
4/12/2016Christoph LengauerInsiderSell18,853$20.14$379,699.4282,845View SEC Filing  
4/6/2016Jeffrey W AlbersCEOSell17,000$20.42$347,140.00109,486View SEC Filing  
12/17/2015Christoph LengauerinsiderSell31,119$25.05$779,530.9572,215View SEC Filing  
11/27/2015Fmr LlcInsiderSell287,415$21.48$6,173,674.20View SEC Filing  
11/24/2015Fmr LlcInsiderSell161,271$20.14$3,247,997.94View SEC Filing  
11/23/2015Fmr LlcInsiderSell189,572$20.15$3,819,875.80View SEC Filing  
11/19/2015Fmr LlcInsiderSell237,218$19.76$4,687,427.68View SEC Filing  
11/17/2015Fmr LlcInsiderSell27,490$20.60$566,294.00View SEC Filing  
11/3/2015Christoph LengauerinsiderSell84,998$21.05$1,789,207.90103,334View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Blueprint Medicines (NASDAQ BPMC) News Headlines

Source:
DateHeadline
Heres Why Blueprint Medicines Fell as Much as 15.1% TodayHere's Why Blueprint Medicines Fell as Much as 15.1% Today
www.msn.com - April 16 at 4:27 PM
Blueprint Fades on Clinical TrialsBlueprint Fades on Clinical Trials
www.baystreet.ca - April 16 at 4:27 PM
Morgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer TherapyMorgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer Therapy
finance.yahoo.com - April 16 at 4:27 PM
Here's Why Blueprint Medicines Fell as Much as 15.1% TodayHere's Why Blueprint Medicines Fell as Much as 15.1% Today
finance.yahoo.com - April 16 at 4:27 PM
Loxo up 6% premarket improved outlook for LOXO-292 after Blueprint data on BLU-667Loxo up 6% premarket improved outlook for LOXO-292 after Blueprint data on BLU-667
seekingalpha.com - April 16 at 9:19 AM
Blueprint Medicine down 9% premarket on early-stage BLU-667 dataBlueprint Medicine down 9% premarket on early-stage BLU-667 data
seekingalpha.com - April 16 at 9:19 AM
Wedbush Raises Blueprint Medicines (BPMC) Price Target to $106.00Wedbush Raises Blueprint Medicines (BPMC) Price Target to $106.00
www.americanbankingnews.com - April 16 at 8:44 AM
JMP Securities Analysts Give Blueprint Medicines (BPMC) a $109.00 Price TargetJMP Securities Analysts Give Blueprint Medicines (BPMC) a $109.00 Price Target
www.americanbankingnews.com - April 16 at 8:17 AM
Blueprint Medicines (BPMC) Stock Rating Upgraded by BidaskClubBlueprint Medicines (BPMC) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 16 at 7:00 AM
Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid TumorsBlueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors
www.prnewswire.com - April 15 at 10:12 AM
Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667
www.prnewswire.com - April 15 at 10:12 AM
Noteworthy Wednesday Option Activity: EVHC, BPMC, ALOGNoteworthy Wednesday Option Activity: EVHC, BPMC, ALOG
www.nasdaq.com - April 11 at 4:30 PM
 Brokerages Expect Blueprint Medicines (BPMC) Will Post Quarterly Sales of $3.18 Million Brokerages Expect Blueprint Medicines (BPMC) Will Post Quarterly Sales of $3.18 Million
www.americanbankingnews.com - April 11 at 2:04 AM
Blueprint Medicines (BPMC) Lowered to Hold at BidaskClubBlueprint Medicines (BPMC) Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 10 at 11:29 AM
-$1.09 EPS Expected for Blueprint Medicines (BPMC) This Quarter-$1.09 EPS Expected for Blueprint Medicines (BPMC) This Quarter
www.americanbankingnews.com - April 9 at 9:20 PM
Blueprint Medicines (BPMC) Rating Reiterated by Jefferies GroupBlueprint Medicines (BPMC) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 9 at 1:19 PM
Blueprint Medicines (BPMC) Price Target Raised to $78.00 at Morgan StanleyBlueprint Medicines (BPMC) Price Target Raised to $78.00 at Morgan Stanley
www.americanbankingnews.com - April 6 at 12:11 PM
Blueprint Medicines (BPMC) Rating Increased to Buy at ValuEngineBlueprint Medicines (BPMC) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 6:27 PM
Wedbush Reiterates "Outperform" Rating for Blueprint Medicines (BPMC)Wedbush Reiterates "Outperform" Rating for Blueprint Medicines (BPMC)
www.americanbankingnews.com - April 1 at 8:06 PM
Blueprint Medicines (BPMC) Downgraded by BidaskClub to BuyBlueprint Medicines (BPMC) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - March 29 at 11:17 AM
Blueprint Medicines Corp (BPMC) Receives Consensus Rating of "Buy" from AnalystsBlueprint Medicines Corp (BPMC) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 10:17 AM
Blueprint Medicines Corp (BPMC) Expected to Announce Quarterly Sales of $3.18 MillionBlueprint Medicines Corp (BPMC) Expected to Announce Quarterly Sales of $3.18 Million
www.americanbankingnews.com - March 25 at 2:34 AM
Blueprint Medicines Corp (BPMC) Expected to Post Earnings of -$1.09 Per ShareBlueprint Medicines Corp (BPMC) Expected to Post Earnings of -$1.09 Per Share
www.americanbankingnews.com - March 23 at 7:24 PM
George Demetri Sells 5,492 Shares of Blueprint Medicines Corp (BPMC) StockGeorge Demetri Sells 5,492 Shares of Blueprint Medicines Corp (BPMC) Stock
www.americanbankingnews.com - March 21 at 7:14 PM
Insider Selling: Blueprint Medicines Corp (BPMC) Insider Sells 2,300 Shares of StockInsider Selling: Blueprint Medicines Corp (BPMC) Insider Sells 2,300 Shares of Stock
www.americanbankingnews.com - March 19 at 7:46 PM
Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018
finance.yahoo.com - March 14 at 5:44 PM
Zacks: Brokerages Expect Blueprint Medicines Corp (BPMC) Will Post Quarterly Sales of $3.18 MillionZacks: Brokerages Expect Blueprint Medicines Corp (BPMC) Will Post Quarterly Sales of $3.18 Million
www.americanbankingnews.com - March 8 at 4:42 AM
Blueprint Medicines Corp (BPMC) CEO Jeffrey W. Albers Sells 20,000 SharesBlueprint Medicines Corp (BPMC) CEO Jeffrey W. Albers Sells 20,000 Shares
www.americanbankingnews.com - March 6 at 6:14 PM
Zacks: Analysts Expect Blueprint Medicines Corp (BPMC) to Post -$1.09 EPSZacks: Analysts Expect Blueprint Medicines Corp (BPMC) to Post -$1.09 EPS
www.americanbankingnews.com - March 6 at 3:20 PM
Blueprint Medicines to Present at Cowen and Company 38th Annual Health Care ConferenceBlueprint Medicines to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:17 AM
Blueprint Medicines Corp (BPMC) Receives Consensus Recommendation of "Buy" from AnalystsBlueprint Medicines Corp (BPMC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 3 at 12:16 PM
Blueprint Medicines Corp (BPMC) Shares Bought by State of Wisconsin Investment BoardBlueprint Medicines Corp (BPMC) Shares Bought by State of Wisconsin Investment Board
www.americanbankingnews.com - March 3 at 8:46 AM
Sei Investments Co. Has $5.62 Million Holdings in Blueprint Medicines Corp (BPMC)Sei Investments Co. Has $5.62 Million Holdings in Blueprint Medicines Corp (BPMC)
www.americanbankingnews.com - March 3 at 8:00 AM
Blueprint Medicines Corp (BPMC) Shares Bought by Swiss National BankBlueprint Medicines Corp (BPMC) Shares Bought by Swiss National Bank
www.americanbankingnews.com - March 2 at 7:32 PM
Blueprint Medicines Corp (BPMC) Director Sells $2,197,250.00 in StockBlueprint Medicines Corp (BPMC) Director Sells $2,197,250.00 in Stock
www.americanbankingnews.com - March 2 at 6:20 PM
27,065 Shares in Blueprint Medicines Corp (BPMC) Acquired by EAM Investors LLC27,065 Shares in Blueprint Medicines Corp (BPMC) Acquired by EAM Investors LLC
www.americanbankingnews.com - March 2 at 1:32 PM
Hudson Bay Capital Management LP Invests $2.26 Million in Blueprint Medicines Corp (BPMC) StockHudson Bay Capital Management LP Invests $2.26 Million in Blueprint Medicines Corp (BPMC) Stock
www.americanbankingnews.com - March 2 at 12:48 PM
Spark Investment Management LLC Purchases 10,400 Shares of Blueprint Medicines Corp (BPMC)Spark Investment Management LLC Purchases 10,400 Shares of Blueprint Medicines Corp (BPMC)
www.americanbankingnews.com - February 27 at 4:34 PM
Blueprint Medicines Corp (BPMC) Stake Increased by Schwab Charles Investment Management Inc.Blueprint Medicines Corp (BPMC) Stake Increased by Schwab Charles Investment Management Inc.
www.americanbankingnews.com - February 27 at 5:50 AM
Blueprint Medicines Corp Forecasted to Post FY2022 Earnings of $0.09 Per Share (BPMC)Blueprint Medicines Corp Forecasted to Post FY2022 Earnings of $0.09 Per Share (BPMC)
www.americanbankingnews.com - February 26 at 10:14 AM
Blueprint Medicines Corp (BPMC) to Post Q1 2018 Earnings of ($1.13) Per Share, Jefferies Group ForecastsBlueprint Medicines Corp (BPMC) to Post Q1 2018 Earnings of ($1.13) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - February 26 at 3:16 AM
Blueprint Medicines (BPMC) Downgraded to "Sell" at Zacks Investment ResearchBlueprint Medicines (BPMC) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 23 at 7:24 PM
Brokers Offer Predictions for Blueprint Medicines Corps FY2022 Earnings (BPMC)Brokers Offer Predictions for Blueprint Medicines Corp's FY2022 Earnings (BPMC)
www.americanbankingnews.com - February 23 at 5:28 PM
Blueprint Medicines Target of Unusually Large Options Trading (BPMC)Blueprint Medicines Target of Unusually Large Options Trading (BPMC)
www.americanbankingnews.com - February 23 at 8:26 AM
Blueprint Medicines (BPMC) Buy Rating Reiterated at CowenBlueprint Medicines' (BPMC) Buy Rating Reiterated at Cowen
www.americanbankingnews.com - February 21 at 8:16 PM
Was Blueprint Medicines Corporation’s (NASDAQ:BPMC) Earnings Decline A Part Of Broader Industry Downturn?Was Blueprint Medicines Corporation’s (NASDAQ:BPMC) Earnings Decline A Part Of Broader Industry Downturn?
finance.yahoo.com - February 21 at 4:42 PM
Blueprint Medicines (BPMC) Posts Quarterly  Earnings Results, Misses Expectations By $0.16 EPSBlueprint Medicines (BPMC) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS
www.americanbankingnews.com - February 21 at 9:44 AM
Blueprint Medicines Corp. to Host Earnings CallBlueprint Medicines Corp. to Host Earnings Call
finance.yahoo.com - February 21 at 9:31 AM
 Brokerages Expect Blueprint Medicines Corp (BPMC) Will Announce Quarterly Sales of $5.09 Million Brokerages Expect Blueprint Medicines Corp (BPMC) Will Announce Quarterly Sales of $5.09 Million
www.americanbankingnews.com - February 19 at 1:48 AM
Zacks: Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Announce Earnings of -$1.07 Per ShareZacks: Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Announce Earnings of -$1.07 Per Share
www.americanbankingnews.com - February 17 at 11:16 PM

SEC Filings

Blueprint Medicines (NASDAQ:BPMC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Blueprint Medicines (NASDAQ:BPMC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Blueprint Medicines (NASDAQ BPMC) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.